



Pixium Vision announces the publication in *Nature Communications* of peer-reviewed clinical data demonstrating the clinical benefit of the Prima System in Dry AMD patients

Paris, France, January 27, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today the publication of a paper in *Nature Communications*, outlining further data with its Prima System, a photovoltaic substitute of photoreceptors providing simultaneous use of the central prosthetic and peripheral natural vision in atrophic dry age-related macular degeneration (AMD).

The peer-reviewed paper in *Nature Communications*, entitled “Simultaneous Perception of Prosthetic and Natural Vision in AMD Patients”, outlines how five patients with geographic atrophy enrolled in the French feasibility study successfully were implanted subretinally with the wireless PRIMA implant and how their vision improved meaningfully 24 months after implantation. While all patients had a sight in the studied eye before implantation that would be defined as legally blind in many countries, all demonstrated a sighted eyesight while using the electronic magnification up to a factor of 8. In practice this means progressing from being able to only perceive shapes, to being able to read text on a page.

These are the first peer-reviewed clinical data for the Prima System showing simultaneous use of the central prosthetic and peripheral natural vision in dry AMD. The data showed Landolt acuity of 1.17 ± 0.13 pixels which demonstrates that the resolution of the perception is close to the resolution of the chip. Thanks to the “zoom” function the Prima System is equipped with (electronic magnification up to a factor of 8), patients were able to improve their prosthetic visual acuity from 20/182 to 20/428 without the system, a level defined as legal blindness in many countries, to a range of 20/63-20/98. This represents a meaningful improvement of 5 to 6 lines on a letter chart over their vision without the Prima system.

“The peer-reviewed publication of these data in the prestigious journal of Nature Communications demonstrates the validation by our peers of the highly innovative and promising nature of our Prima System for the treatment of dry AMD,” said **Lloyd Diamond, CEO of Pixium Vision**. *“The data highlighted in this publication not only support that patients can combine their remaining peripheral vision with our bionic vision, that the resolution of perception is close to the resolution of the implant, and also very importantly exhibit that the natural peripheral vision is not reduced over time following the implantation. The pivotal PRIMAVera study is ongoing in Europe and we look forward to demonstrating these great benefits in a larger pool of patients, targeting to bring the Prima System to the European market in 2024”.*

The key take-aways from the data published in *Nature Communications* are:

- The Prima System implant was generally well tolerated over the 18-24 months period
- The synchronous perception of natural and prosthetic vision has been demonstrated
- Environmental background light was well tolerated
- A visual acuity of up to 20/63, significantly better than the legal blindness of 20/200 in many countries, was achieved
- Resolution of perception is close to the resolution of the implant (1.2 pixels)
- The benefits of the Prima System were maintained over 24 months
- The natural vision was not reduced over time following the implantation of the implant

In Europe, we intend to demonstrate the safety and the benefits of the Prima System in Pixium Vision's pivotal PRIMavera study with read-out expected towards the end of 2023 and regulatory submission for market approval soon after. In the US, a feasibility study is also ongoing.

The full peer-reviewed *Nature Communications* paper is available online [here](#).

About Pixium Vision

Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision's bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as "Entreprise Innovante" by Bpifrance.

Forward-Looking Statements. This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors ("Facteurs de Risques") section of the Company's 2021 Half-Year Financial Report and other documents the Company files with the AMF, which is available on the AMF website (www.amf-france.org) or on the Company's website.

For more information: <http://www.pixium-vision.com/fr>

Follow us on [@PixiumVision](#); www.facebook.com/pixiumvision

www.linkedin.com/company/pixium-vision



Pixium Vision is listed on Euronext Growth Paris.
Euronext ticker: ALPIX - ISIN: FR0011950641

Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.

Pixium Vision is included in the Euronext GROWTH ALLSHARE index

Contacts

Pixium Vision

Offer Nonhoff
Chief Financial Officer
investors@pixium-vision.com
+33 1 76 21 47 68

Media Relations

LifeSci Advisors
Sophie Baumont
sophie@lifesciadvisors.com
+33 6 27 74 74 49

Investor Relations

LifeSci Advisors
Guillaume van Renterghem
gvanrenterghem@lifesciadvisors.com
+41 76 735 01 31